Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

Immunoglobulin G level variations in treated chronic inflammatory demyelinating polyneuropathy: clues for future treatment regimens?

Rajabally YA, Wong SL, Kearney DA.

J Neurol. 2013 Aug;260(8):2052-6. doi: 10.1007/s00415-013-6938-7. Epub 2013 May 5.

PMID:
23645220
2.

Serum IgG levels in IV immunoglobulin treated chronic inflammatory demyelinating polyneuropathy.

Kuitwaard K, van Doorn PA, Vermeulen M, van den Berg LH, Brusse E, van der Kooi AJ, van der Pol WL, van Schaik IN, Notermans N, Tio-Gillen AP, van Rijs W, van Gelder T, Jacobs BC.

J Neurol Neurosurg Psychiatry. 2013 Aug;84(8):859-61. doi: 10.1136/jnnp-2012-304670. Epub 2013 Mar 28.

PMID:
23538070
3.

Variability in intravenous immunoglobulin G regimens for autoimmune neuromuscular disorders.

Broyles R, Rodden L, Riley P, Berger M.

Postgrad Med. 2013 Mar;125(2):65-72. doi: 10.3810/pgm.2013.03.2619.

PMID:
23816772
4.

Serum IgG levels as biomarkers for optimizing IVIg therapy in CIDP.

van Doorn PA, Kuitwaard K, Jacobs BC.

J Peripher Nerv Syst. 2011 Jun;16 Suppl 1:38-40. doi: 10.1111/j.1529-8027.2011.00304.x.

PMID:
21696496
5.

Dose of intravenous immunoglobulins in chronic inflammatory demyelinating polyneuropathy.

Rajabally YA, Seow H, Wilson P.

J Peripher Nerv Syst. 2006 Dec;11(4):325-9.

PMID:
17117941
6.

[Intermittent intravenous immunoglobulin infusion prevented relapses in patients with remission-exacerbation type chronic inflammatory demyelinating polyradiculoneuropathy].

Kanda F, Sekiguchi K, Oishi K, Hamaguchi H, Mitsui S, Kobessho H, Higuchi M, Shirafuji T, Ishihara H.

Rinsho Shinkeigaku. 2006 Mar;46(3):236-8. Japanese.

PMID:
16642939
7.

Changes in serum macrophage-related factors in patients with chronic inflammatory demyelinating polyneuropathy caused by intravenous immunoglobulin therapy.

Ochi K, Kohriyama T, Higaki M, Ikeda J, Harada A, Nakamura S.

J Neurol Sci. 2003 Apr 15;208(1-2):43-50.

PMID:
12639724
8.

Optimization of intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy evaluated by grip strength measurement.

Kokubun N, Sada T, Yuki N, Okabe M, Hirata K.

Eur Neurol. 2013;70(1-2):65-9. doi: 10.1159/000350287. Epub 2013 Jun 19.

PMID:
23796651
9.

Chronic inflammatory demyelinating polyneuropathy (CIDP): change of serum IgG dimer levels during treatment with intravenous immunoglobulins.

Ritter C, Bobylev I, Lehmann HC.

J Neuroinflammation. 2015 Aug 14;12:148. doi: 10.1186/s12974-015-0361-1.

10.
11.

Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial.

Nobile-Orazio E, Cocito D, Jann S, Uncini A, Beghi E, Messina P, Antonini G, Fazio R, Gallia F, Schenone A, Francia A, Pareyson D, Santoro L, Tamburin S, Macchia R, Cavaletti G, Giannini F, Sabatelli M; IMC Trial Group..

Lancet Neurol. 2012 Jun;11(6):493-502. doi: 10.1016/S1474-4422(12)70093-5. Epub 2012 May 10.

PMID:
22578914
12.

Mechanisms of IVIG efficacy in chronic inflammatory demyelinating polyneuropathy.

Tackenberg B, Nimmerjahn F, Lünemann JD.

J Clin Immunol. 2010 May;30 Suppl 1:S65-9. doi: 10.1007/s10875-010-9398-1. Review.

PMID:
20424898
13.

Nerve excitability changes after intravenous immunoglobulin infusions in multifocal motor neuropathy and chronic inflammatory demyelinating neuropathy.

Boërio D, Créange A, Hogrel JY, Guéguen A, Bertrand D, Lefaucheur JP.

J Neurol Sci. 2010 May 15;292(1-2):63-71. doi: 10.1016/j.jns.2010.02.002. Epub 2010 Mar 10.

PMID:
20219211
14.

[Efficacy and availability of intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy].

Iijima M, Koike H, Sobue G.

Nihon Rinsho. 2012 Apr;70(4):715-21. Review. Japanese.

PMID:
22568158
15.

Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome.

Kuitwaard K, de Gelder J, Tio-Gillen AP, Hop WC, van Gelder T, van Toorenenbergen AW, van Doorn PA, Jacobs BC.

Ann Neurol. 2009 Nov;66(5):597-603. doi: 10.1002/ana.21737.

PMID:
19938102
16.

Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study).

Léger JM, De Bleecker JL, Sommer C, Robberecht W, Saarela M, Kamienowski J, Stelmasiak Z, Mielke O, Tackenberg B, Shebl A, Bauhofer A, Zenker O, Merkies IS; PRIMA study investigators..

J Peripher Nerv Syst. 2013 Jun;18(2):130-40. doi: 10.1111/jns5.12017.

17.
18.

Acute motor response following a single IVIG treatment course in chronic inflammatory demyelinating polyneuropathy.

Harbo T, Andersen H, Jakobsen J.

Muscle Nerve. 2009 Apr;39(4):439-47. doi: 10.1002/mus.21305.

PMID:
19229876
19.

Serum trough IgG level and annual intravenous immunoglobulin dose are not related to body size in patients on regular replacement therapy.

Khan S, Grimbacher B, Boecking C, Chee R, Allgar V, Holding S, Wong G, Huissoon A, Herriot R, Doré P, Sewell W.

Drug Metab Lett. 2011 Apr;5(2):132-6.

PMID:
21457142
20.

The effect of IgG levels on the number of natural killer cells and their Fc receptors in chronic inflammatory demyelinating polyradiculoneuropathy.

Bohn AB, Nederby L, Harbo T, Skovbo A, Vorup-Jensen T, Krog J, Jakobsen J, Hokland ME.

Eur J Neurol. 2011 Jun;18(6):919-24. doi: 10.1111/j.1468-1331.2010.03333.x. Epub 2011 Jan 11.

PMID:
21219545

Supplemental Content

Support Center